Fiedorczuk et al. found that a total of 14 sets of candidate biomarkers displayed differences in levels or concentrations in OSAHS patients compared to non-OSA controls, and decreased after OSA treatment: IL-6, leptin, IL-8, IGF-1, etc [7]. The gene discussed is CXCL8; the disease is obstructive sleep apnea syndrome.